HC Wainwright Reiterates Buy Rating for Gain Therapeutics (NASDAQ:GANX)

HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report released on Monday,Benzinga reports. The firm currently has a $8.00 target price on the stock.

A number of other research analysts also recently issued reports on the company. Roth Mkm reiterated a “buy” rating and set a $7.00 price objective on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Scotiabank started coverage on shares of Gain Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target for the company. Finally, Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Price Performance

NASDAQ GANX opened at $2.47 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The business’s fifty day moving average is $2.23 and its 200 day moving average is $2.01. The company has a market capitalization of $65.52 million, a PE ratio of -2.25 and a beta of 0.14. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $4.63.

Institutional Trading of Gain Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in shares of Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after purchasing an additional 88,236 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Gain Therapeutics by 83.6% during the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after buying an additional 44,750 shares in the last quarter. Marshall Wace LLP bought a new stake in Gain Therapeutics in the 4th quarter worth approximately $198,000. Northern Trust Corp raised its holdings in shares of Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after acquiring an additional 39,642 shares in the last quarter. Finally, Bridgeway Capital Management LLC bought a new position in shares of Gain Therapeutics during the 4th quarter valued at approximately $65,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.